Non-steroidal anti-inflammatory pain relief drug Nimesulide is prescribed for the treatment of acute pain, Primary dysmennorhea and also to treat degenerative joint disease.
The drug is developed by Helsinn Healthcare. Medicines containing Nimesulide are on the market since 1985 and are authorised in a number of Member States.
Nimesulide also improves the skin tone and to increase in energy levels. Food, gender and advanced age have negligible effects on Nimesulide pharmacokinetics.
Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.
Clinical studies have been carried out in a wide variety of acute inflammatory and painful conditions with the aim of evaluating the analgesic activity of nimesulide in comparison to placebo and to some of the most common NSAIDs.
In these studies, the efficacy of nimesulide was consistently superior to placebo with a particularly fast onset of the analgesic action.
This rapid onset of analgesic action shows meaningful reductions in pain and inflammation observed within 15 minutes from drug intake.
Unlike, other NSAIDs, the chemical structure of nimesulide does not contain a carboxylic group but a sulfonanilide moiety as the acidic group.
As with all drugs, therapy appropriateness when using nimesulide is of outmost importance to safeguard patient’s health and guarantee the product’s therapeutic value.
The drug is developed by Helsinn Healthcare. Medicines containing Nimesulide are on the market since 1985 and are authorised in a number of Member States.
Nimesulide also improves the skin tone and to increase in energy levels. Food, gender and advanced age have negligible effects on Nimesulide pharmacokinetics.
Its multifactorial mode of action gives it a unique and broad action on inflammatory processes.
Clinical studies have been carried out in a wide variety of acute inflammatory and painful conditions with the aim of evaluating the analgesic activity of nimesulide in comparison to placebo and to some of the most common NSAIDs.
In these studies, the efficacy of nimesulide was consistently superior to placebo with a particularly fast onset of the analgesic action.
This rapid onset of analgesic action shows meaningful reductions in pain and inflammation observed within 15 minutes from drug intake.
Unlike, other NSAIDs, the chemical structure of nimesulide does not contain a carboxylic group but a sulfonanilide moiety as the acidic group.
As with all drugs, therapy appropriateness when using nimesulide is of outmost importance to safeguard patient’s health and guarantee the product’s therapeutic value.
No comments:
Post a Comment